Enclomiphene Citrate: Renal Protection or Renal Risk?

The Direct Answer

The evidence supports a narrow conclusion: enclomiphene can raise endogenous testosterone and gonadotropins in selected men with secondary hypogonadism while preserving sperm concentration over the short study periods. It does not establish renal protection [1-4].

That distinction matters. A study can report hormone and semen outcomes without being able to rule out uncommon kidney adverse events, quantify safety in chronic kidney disease, or show a change in kidney function. The absence of a renal endpoint is not evidence of either benefit or harm.

What the Enclomiphene Trials Actually Measured

The correct PubMed record for the Kim phase III paper is PMID 26496621 [1].

Why a Testosterone Increase Is Not Proof of Kidney Benefit

Associations among testosterone, anemia, metabolic health, and kidney disease do not demonstrate that raising testosterone with enclomiphene improves renal outcomes. That would require a trial designed around endpoints such as:

• change in estimated glomerular filtration rate (eGFR);
• urine albumin-to-creatinine ratio;
• acute kidney injury;
• progression to a higher CKD stage; or
• a prespecified renal adverse-event analysis.

The enclomiphene trials cited here did not answer those questions. Mechanistic reasoning should therefore be labeled as a hypothesis, not converted into a clinical benefit claim.

What Is Known About Renal Risk?

There is no FDA-approved enclomiphene prescribing information with a renal-impairment section, validated dose adjustment, or postmarketing safety database comparable to an approved drug label. FDA materials state that no FDA-approved drug product contains enclomiphene citrate. They also describe why the submitted application did not establish the clinical benefit needed for approval [6].

This creates two separate uncertainties:

1. Dedicated renal safety is unknown. Short hormone trials in selected participants cannot characterize safety across CKD stages.
2. Product-specific pharmacology is not standardized by an approved label. There is no FDA-reviewed enclomiphene dosing instruction for reduced kidney function.

It would be inaccurate to turn those gaps into claims that enclomiphene is “kidney safe,” “hepatically cleared so no renal adjustment is needed,” or “protective.”

If You Have Kidney Disease or an Abnormal Creatinine

An abnormal creatinine while using enclomiphene should be evaluated on its own merits. Hydration, muscle mass, supplements, other medicines, urinary obstruction, diabetes, blood pressure, and underlying kidney disease can all affect renal measurements. A temporal association does not prove enclomiphene caused the change, but it also should not be dismissed because older trials focused on other endpoints.

Questions to take to the prescribing clinician include:

• What was the pre-treatment creatinine and eGFR?
• Is the change persistent on repeat testing?
• Are urine albumin, urinalysis, potassium, or blood pressure abnormal?
• Were any medicines or supplements started at the same time?
• Does the indication and expected benefit justify continued exposure while the change is evaluated?

There is no evidence-based enclomiphene-specific threshold or universal testing interval to substitute for that clinical assessment.

What the Evidence Supports—and What It Does Not

Bottom Line

Enclomiphene is a testosterone-restoring SERM with human evidence centered on hormones and fertility. Kidney protection is an unsupported extrapolation. Kidney harm has not been adequately characterized in a dedicated renal population. The most accurate counseling is to state both limits plainly and evaluate kidney abnormalities using the patient's baseline, comorbidities, concomitant treatments, and repeat measurements.